EP1891080A2 - Neue phosphorhaltige thyromimetika - Google Patents
Neue phosphorhaltige thyromimetikaInfo
- Publication number
- EP1891080A2 EP1891080A2 EP06760469A EP06760469A EP1891080A2 EP 1891080 A2 EP1891080 A2 EP 1891080A2 EP 06760469 A EP06760469 A EP 06760469A EP 06760469 A EP06760469 A EP 06760469A EP 1891080 A2 EP1891080 A2 EP 1891080A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- optionally substituted
- alkyl
- group
- aryl
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052698 phosphorus Inorganic materials 0.000 title claims description 49
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title claims description 45
- 239000011574 phosphorus Substances 0.000 title claims description 45
- 230000000929 thyromimetic effect Effects 0.000 title claims description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 377
- 239000000651 prodrug Substances 0.000 claims abstract description 151
- 229940002612 prodrug Drugs 0.000 claims abstract description 151
- 150000003839 salts Chemical class 0.000 claims abstract description 75
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims abstract description 66
- 239000013078 crystal Substances 0.000 claims abstract description 43
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 26
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 18
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 17
- 208000008589 Obesity Diseases 0.000 claims abstract description 16
- 235000020824 obesity Nutrition 0.000 claims abstract description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 15
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 15
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 14
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 12
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 10
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims abstract description 7
- 208000011661 metabolic syndrome X Diseases 0.000 claims abstract description 7
- -1 difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio Chemical group 0.000 claims description 655
- 125000004429 atom Chemical group 0.000 claims description 268
- 125000000217 alkyl group Chemical group 0.000 claims description 223
- 229910052739 hydrogen Inorganic materials 0.000 claims description 214
- 239000001257 hydrogen Substances 0.000 claims description 213
- 229910052799 carbon Inorganic materials 0.000 claims description 182
- 125000005842 heteroatom Chemical group 0.000 claims description 171
- 125000003118 aryl group Chemical group 0.000 claims description 144
- 125000004122 cyclic group Chemical group 0.000 claims description 117
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 112
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 109
- 238000000034 method Methods 0.000 claims description 104
- 229910052736 halogen Inorganic materials 0.000 claims description 96
- 150000002367 halogens Chemical class 0.000 claims description 96
- 229910052721 tungsten Inorganic materials 0.000 claims description 91
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 89
- 125000001072 heteroaryl group Chemical group 0.000 claims description 79
- 210000004185 liver Anatomy 0.000 claims description 79
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 65
- 108090000623 proteins and genes Proteins 0.000 claims description 65
- 125000004432 carbon atom Chemical group C* 0.000 claims description 64
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 59
- 230000001965 increasing effect Effects 0.000 claims description 58
- 125000003107 substituted aryl group Chemical group 0.000 claims description 58
- 241001465754 Metazoa Species 0.000 claims description 54
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 54
- 150000001721 carbon Chemical group 0.000 claims description 53
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 52
- 229910052760 oxygen Inorganic materials 0.000 claims description 49
- 229940036555 thyroid hormone Drugs 0.000 claims description 48
- 239000005495 thyroid hormone Substances 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 46
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 45
- 229910052717 sulfur Inorganic materials 0.000 claims description 44
- 102000004217 thyroid hormone receptors Human genes 0.000 claims description 43
- 108090000721 thyroid hormone receptors Proteins 0.000 claims description 43
- 210000002216 heart Anatomy 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 230000014509 gene expression Effects 0.000 claims description 35
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 229910052720 vanadium Inorganic materials 0.000 claims description 33
- 125000004423 acyloxy group Chemical group 0.000 claims description 30
- 125000000304 alkynyl group Chemical group 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 30
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 26
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 25
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 24
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 23
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 22
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 208000004930 Fatty Liver Diseases 0.000 claims description 15
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 231100001274 therapeutic index Toxicity 0.000 claims description 14
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims description 12
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 12
- 125000005750 substituted cyclic group Chemical group 0.000 claims description 12
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 208000010706 fatty liver disease Diseases 0.000 claims description 11
- 108010001831 LDL receptors Proteins 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 9
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 102000000853 LDL receptors Human genes 0.000 claims description 8
- 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 claims description 7
- 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 claims description 7
- 208000016097 disease of metabolism Diseases 0.000 claims description 7
- 230000001976 improved effect Effects 0.000 claims description 7
- 230000007863 steatosis Effects 0.000 claims description 7
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 5
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 5
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 claims description 5
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 claims description 5
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 150000001735 carboxylic acids Chemical group 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 101100011750 Mus musculus Hsp90b1 gene Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 101150117196 tra-1 gene Proteins 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 160
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 48
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 35
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 35
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 33
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 30
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 29
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 22
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims 13
- 125000004043 oxo group Chemical group O=* 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000000547 substituted alkyl group Chemical group 0.000 claims 11
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 11
- 125000004434 sulfur atom Chemical group 0.000 claims 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 125000000524 functional group Chemical group 0.000 claims 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 101
- 230000000694 effects Effects 0.000 description 60
- 229940116254 phosphonic acid Drugs 0.000 description 45
- 235000012000 cholesterol Nutrition 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 31
- 125000002947 alkylene group Chemical group 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 230000002440 hepatic effect Effects 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 108010010234 HDL Lipoproteins Proteins 0.000 description 20
- 102000015779 HDL Lipoproteins Human genes 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 210000001685 thyroid gland Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 19
- 201000010099 disease Diseases 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 108010007622 LDL Lipoproteins Proteins 0.000 description 17
- 102000007330 LDL Lipoproteins Human genes 0.000 description 17
- 102000011923 Thyrotropin Human genes 0.000 description 17
- 108010061174 Thyrotropin Proteins 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 17
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 206010022489 Insulin Resistance Diseases 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 14
- 230000004580 weight loss Effects 0.000 description 14
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 13
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 13
- 102100033451 Thyroid hormone receptor beta Human genes 0.000 description 13
- 102000004895 Lipoproteins Human genes 0.000 description 12
- 108090001030 Lipoproteins Proteins 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000004110 gluconeogenesis Effects 0.000 description 12
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 11
- 230000036284 oxygen consumption Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 210000005229 liver cell Anatomy 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000008437 mitochondrial biogenesis Effects 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 9
- 150000003009 phosphonic acids Chemical class 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical class C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000002641 glycemic effect Effects 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000003470 mitochondria Anatomy 0.000 description 8
- 210000000633 nuclear envelope Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 7
- 208000017170 Lipid metabolism disease Diseases 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000000923 atherogenic effect Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 208000003532 hypothyroidism Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000032928 Dyslipidaemia Diseases 0.000 description 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 6
- 206010020850 Hyperthyroidism Diseases 0.000 description 6
- 210000003486 adipose tissue brown Anatomy 0.000 description 6
- 210000000593 adipose tissue white Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000004190 glucose uptake Effects 0.000 description 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 6
- 201000008980 hyperinsulinism Diseases 0.000 description 6
- 230000002989 hypothyroidism Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000004130 lipolysis Effects 0.000 description 6
- 230000037323 metabolic rate Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 5
- 229940126657 Compound 17 Drugs 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 5
- 101000802091 Homo sapiens Thyroid hormone-inducible hepatic protein Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000020832 chronic kidney disease Diseases 0.000 description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 4
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 4
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 4
- 206010029164 Nephrotic syndrome Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 4
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 4
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 4
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 4
- 229960001456 adenosine triphosphate Drugs 0.000 description 4
- 125000001769 aryl amino group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000004132 lipogenesis Effects 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- OZYQIQVPUZANTM-UHFFFAOYSA-N 2-[3,5-dichloro-4-(4-hydroxy-3-propan-2-ylphenoxy)phenyl]acetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(CC(O)=O)=CC=2Cl)Cl)=C1 OZYQIQVPUZANTM-UHFFFAOYSA-N 0.000 description 3
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 3
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 3
- 208000006029 Cardiomegaly Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 101000904460 Encephalitozoon cuniculi (strain GB-M1) Probable glycerol-3-phosphate dehydrogenase Proteins 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 3
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 3
- 108010033266 Lipoprotein(a) Proteins 0.000 description 3
- 102000057248 Lipoprotein(a) Human genes 0.000 description 3
- NMNFDTCOWIDEAV-UHFFFAOYSA-N OP(O)=O.OP(O)=O Chemical compound OP(O)=O.OP(O)=O NMNFDTCOWIDEAV-UHFFFAOYSA-N 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000003520 lipogenic effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 229940035437 1,3-propanediol Drugs 0.000 description 2
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 101000666228 Danio rerio Thyroid hormone receptor alpha-A Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 description 2
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 description 2
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 description 2
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 description 2
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 2
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 108010078702 Nuclear Respiratory Factors Proteins 0.000 description 2
- 102000014967 Nuclear Respiratory Factors Human genes 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 description 2
- 208000024799 Thyroid disease Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010023795 VLDL receptor Proteins 0.000 description 2
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000005354 acylalkyl group Chemical group 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004882 diastolic arterial blood pressure Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002359 drug metabolite Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 208000007345 glycogen storage disease Diseases 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- 108010064060 high density lipoprotein receptors Proteins 0.000 description 2
- 102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 102000006255 nuclear receptors Human genes 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004873 systolic arterial blood pressure Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000007944 thiolates Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 208000021510 thyroid gland disease Diseases 0.000 description 2
- 229960000874 thyrotropin Drugs 0.000 description 2
- 230000001748 thyrotropin Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229940035722 triiodothyronine Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FMTNMUJSOHIDRT-UHFFFAOYSA-N 1,3,2-dioxaphosphonane Chemical compound C1CCCOPOCC1 FMTNMUJSOHIDRT-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- UOJMJBUYXYEPFX-UHFFFAOYSA-N 2-[4-(4-hydroxy-3-propan-2-ylphenoxy)-3,5-dimethylanilino]-2-oxoacetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(NC(=O)C(O)=O)=CC=2C)C)=C1 UOJMJBUYXYEPFX-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HZCBWYNLGPIQRK-UHFFFAOYSA-N 3,3',5'-Triiodothyronine Natural products IC1=CC(CC(N)C(O)=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-UHFFFAOYSA-N 0.000 description 1
- HZCBWYNLGPIQRK-LBPRGKRZSA-N 3,3',5'-triiodo-L-thyronine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-LBPRGKRZSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-RVOWOUOISA-N 7alpha-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-RVOWOUOISA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- DEVWEFBXXYMHIL-UHFFFAOYSA-N CCCOP(O)=O Chemical compound CCCOP(O)=O DEVWEFBXXYMHIL-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 description 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101150073133 Cpt1a gene Proteins 0.000 description 1
- 102000005297 Cytochrome P-450 CYP4A Human genes 0.000 description 1
- 108010081498 Cytochrome P-450 CYP4A Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010021075 HDL2 Lipoproteins Proteins 0.000 description 1
- 108010021078 HDL3 Lipoproteins Proteins 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 108050006747 Hepatic lipases Proteins 0.000 description 1
- 102000019267 Hepatic lipases Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001028852 Homo sapiens Fructose-1,6-bisphosphatase 1 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LKYWLLWWYBVUPP-XOCLESOZSA-L Liotrix Chemical compound [Na+].[Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1.IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 LKYWLLWWYBVUPP-XOCLESOZSA-L 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 108010045510 NADPH-Ferrihemoprotein Reductase Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000000524 Nuclear Respiratory Factor 1 Human genes 0.000 description 1
- 108010016592 Nuclear Respiratory Factor 1 Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 108010038912 Retinoid X Receptors Proteins 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- QNAZTOHXCZPOSA-UHFFFAOYSA-N Sobetirome Chemical compound C1=C(O)C(C(C)C)=CC(CC=2C(=CC(OCC(O)=O)=CC=2C)C)=C1 QNAZTOHXCZPOSA-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003329 adenohypophysis hormone Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- VNVRRNRPVIZREH-UHFFFAOYSA-N carbamoylphosphonic acid Chemical compound NC(=O)P(O)(O)=O VNVRRNRPVIZREH-UHFFFAOYSA-N 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005831 deiodination reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- KFGFLEOUNBSLSO-UHFFFAOYSA-N dioxaphosphonane Chemical compound C1CCCPOOCC1 KFGFLEOUNBSLSO-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- SBXXSUDPJJJJLC-YDALLXLXSA-M liothyronine sodium Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 SBXXSUDPJJJJLC-YDALLXLXSA-M 0.000 description 1
- 229960002018 liothyronine sodium Drugs 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000005817 liver abnormality Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- CGJMROBVSBIBKP-UHFFFAOYSA-N malonamic acid Chemical compound NC(=O)CC(O)=O CGJMROBVSBIBKP-UHFFFAOYSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 108010068815 steroid hormone 7-alpha-hydroxylase Proteins 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 1
- 238000011680 zucker rat Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/36—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4075—Esters with hydroxyalkyl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4426—Amides of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4465—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Definitions
- T3 is metabolized to inactive metabolites via a variety of pathways, including pathways involving deiodination, glucuronidation, sulfation, deamination, and decarboxylation. Most of the circulating T4 and T3 is eliminated through the liver.
- THs have profound physiological effects in animals and humans.
- Hyperthyroidism is associated with increased body temperature, general nervousness, weight loss despite increased appetite, muscle weakness and fatigue, increased bone resorption and enhanced calcification, and a variety of cardiovascular changes, including increased heart rate, increased stroke volume, increased cardiac index, cardiac hypertrophy, decreased peripheral vascular resistance, and increased pulse pressure. Hypothyroidism is generally associated with the opposite effects.
- Lp(a) is a hepatic acute phase protein that promotes the binding of LDL to cell surfaces independent of LDL receptors. Accordingly, Lp(a) is thought to provide supplementary cholesterol to certain cells, e.g., cells involved in inflammation or repair. Lp(a) is an independent risk factor for premature atherosclerosis. Lp(a) is synthesized in the liver.
- TH therapy is reported to stimulate hepatic gluconeogenesis. Enzymes specific to gluconeogenesis and important for controlling the pathway and its physiological role of producing glucose are known to be influenced by TH therapy. Phosphoenolpyruvate carboxykinase (PEPCK) is upregulated by TH (Park et al, J. Biol. Chem. 274:211 (1999)) whereas others have found that glucose 6-phosphatase is upregulated (Feng et al., MoI. Endocrinol. 14:947 (2000)). TH therapy is also associated with reduced glycogen levels.
- PEPCK Phosphoenolpyruvate carboxykinase
- FIG. 1b depicts the dose response of serum cholesterol levels to
- Figure 3 a depicts the effect of Compound 17 on the weight of the heart in cholesterol fed rats.
- Figure 3b depicts the effect of Compound 7 on the weight of the heart in cholesterol fed rats.
- Figure 4a depicts the effect of Compound 17 on cardiac GPDH activity in cholesterol fed rats.
- Figure 4b depicts the effect of Compound 7 on cardiac GPDH activity in cholesterol fed rats.
- Figure 5 depicts the dose response of serum cholesterol levels to
- Some of the compounds of Formula I, II, III, VIII, and X have asymmetric centers. Thus included in the present invention are racemic mixtures, enantiomerically enriched mixtures, diastereomeric mixtures, including diastereomeric enriched mixtures, and individual stereoisomers of the compounds of Formula I, II, III, VIII, and X and prodrugs thereof.
- Carbocyclic aryl groups are groups which have 6-14 ring atoms wherein the ring atoms on the aromatic ring are carbon atoms.
- Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and polycyclic or fused compounds such as optionally substituted naphthyl groups.
- -aralkyl refers to an alkylene group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, and may be optionally substituted. "Heteroarylalkyl” refers to an alkylene group substituted with a heteroaryl group.
- acyl refers to -C(O)R where R is alkyl, heterocycloalkyl, or aryl.
- -carboxylamido refers to -CONR 2 where each R is independently hydrogen or alkyl.
- halogen refers to -F, -Cl, -Br and -I.
- sulphonyl or “sulfonyl” refers to -SO 2 R, where R is H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- alkenyl refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon double bond and includes straight-chain, branched-chain and cyclic groups. Alkenyl groups may be optionally substituted. Suitable alkenyl groups include allyl. "1 -alkenyl” refers to alkenyl groups where the double bond is between the first and second carbon atom. If the 1 -alkenyl group is attached to another group, e.g., it is a W substituent attached to the cyclic phosphonate, it is attached at the first carbon.
- alkynyl refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon triple bond and includes straight-chain, branched-chain and cyclic groups. Alkynyl groups may be optionally substituted. Suitable alkynyl groups include ethynyl. "1 -alkynyl” refers to alkynyl groups where the triple bond is between the first and second carbon atom. If the 1 -alkynyl group is attached to another group, e.g., it is a W substituent attached to the cyclic phosphonate, it is attached at the first carbon.
- aryloxyalkyl- refers to an alkyl group substituted with an aryloxy group.
- alkylthio- refers to the group alkyl-S-.
- R and R 1 include -H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- acylalkyl refers to an alkyl-C(O)-alk-, where “alk” is alkylene.
- heteroarylalkyl refers to an alkylene group substituted with a heteroaryl group.
- surrogates of carboxylic acid refers to groups that possess near equal molecular shapes and volumes as carboxylic acid and which exhibit similar physical and biological properties.
- examples of surrogates of carboxylic acid include, but are not limited to, tetrazole, 6-azauracil, acylsulphonamides, thiazolidinedione, hydroxamic acid, oxamic acid, malonamic acid, and carboxylic acid amides.
- the ratio of the compound of the present invention to co-crystal former or solvent may be specified as stoichiometric or non-stoichiometric. 1:1, 1.5:1, 1:1.5, 2:1, 1:2, and 1:3 ratios of APLco-crystal former/solvent are examples of stoichiometric ratios.
- patient means an animal.
- Prodrugs must undergo some form of a chemical transformation to produce the compound that is biologically active or is a precursor of the biologically active compound, hi some cases, the prodrug is biologically active, usually less than the drug itself, and serves to improve drug efficacy or safety through improved oral bioavailability, and/or pharmacodynamic half-life, etc.
- Prodrug forms of compounds may be utilized, for example, to improve bioavailability, improve subject acceptability such as by masking or reducing unpleasant characteristics such as bitter taste or gastrointestinal irritability, alter solubility such as for intravenous use, provide for prolonged or sustained release or delivery, improve ease of formulation, or provide site-specific delivery of the compound.
- Prodrugs are described in The Organic Chemistry of Drug Design and Drag Action, by Richard B.
- esters are possible in which a cyclic alkyl ring is formed. These esters have been shown to generate phosphorus-containing nucleotides inside cells through a postulated sequence of reactions beginning with deesterification and followed by a series of elimination reactions ⁇ e.g., Freed et al, Biochem. Pharm, 35:3193-3198 (1989)).
- alkyloxycarbonyloxymethyl esters as shown in formula A, where R is alkoxy, aryloxy, alkylthio, arylthio, alkylamino, and arylamino; R', and R" are independently -H, alkyl, aryl, alkylaryl, and heterocycloalkyl have been studied in the area of ⁇ -lactam antibiotics (Nishimura et ah, J. Antibiotics 40(l):Sl-90 (1987); for a review see Ferres, H., Drugs of Today, 19:499 (1983)). More recently Cathy, M. S. et al.
- R is -H, alkyl, aryl, alkylaryl, alkoxy, aryloxy, alkylthio, arylthio, alkylamino, arylamino, or cycloalkyl.
- Y is -H, alkyl, aryl, alkylaryl, alkoxy, acyloxy, halogen, amino, alkoxycarbonyl, hydroxy, cyano, and heterocycloalkyl.
- prodrugs of Formula E-3 are an example of "optionally substituted heterocycloalkyl where the cyclic moiety contains a carbonate or thiocarbonate.”
- Propyl phosphonate proesters can also be used to deliver drugs into hepatocytes. These proesters may contain a hydroxyl and hydroxyl group derivatives at the 3 -position of the propyl group as shown in formula F.
- the R and X groups can form a cyclic ring system as shown in formula F.
- One or more of the oxygens of the phosphonate can be esterified.
- prodrugs are possible based on literature reports such as substituted ethyls, for example, bis(trichloroethyl)esters as disclosed by McGuigan, et al, Bioorg Med. Chem. Lett. 3:1207-1210 (1993), and the phenyl and benzyl combined nucleotide esters reported by Meier, C. et al, Bioorg. Med. Chem. Lett. 7:99-104 (1997).
- substituted ethyls for example, bis(trichloroethyl)esters as disclosed by McGuigan, et al, Bioorg Med. Chem. Lett. 3:1207-1210 (1993), and the phenyl and benzyl combined nucleotide esters reported by Meier, C. et al, Bioorg. Med. Chem. Lett. 7:99-104 (1997).
- spot- 14 refers to a 17 kilodalton protein expressed in lipogenic tissues and is postulated to play a role in thyroid hormone stimulation of lipogenesis. (Campbell, MC et al, Endocrinology /0:1210 (2003).
- CPT- 1 refers to carnitine palmitoyltransferase- 1.
- nephrotic syndrome refers to a condition of heavy glomerular proteinuria which is associated with hyperlipidemia, increased risk of cardiovascular disease, and deterioration of renal function.
- the nephrotic dyslipidemia is marked by hypercholesterolemia, hypertriglyceridemia, and elevated plasma concentration and impaired clearance of LDL, VLDL, and IDL.
- Atherogenic dyslipidemia blood fat disorders — mainly high triglycerides and low HDL cholesterol — that foster plaque buildups in artery walls
- Insulin resistance or glucose intolerance the body can't properly use insulin or blood sugar
- thyroid responsive element refers to an element that usually consists of directly repeated half-sites with the consensus sequence AGGTCA. (Harbers et al, Nucleic Acids Res. 24(12):2252-2259 (1996)). TREs contain two half-sites of the AGGTCA motif which can be arranged as direct repeats, inverted repeats, or everted repeats.
- Atherogenic proteins refers to proteins that induce, stimulate, enhance or prolong atherosclerosis and diseases related to atherosclerosis, including but not limited to coronary heart disease. Atherogenic proteins include apoAI and Lp (a).
- the term "significant” or “statistically significant” means a result (i.e. experimental assay result) where the p-value is ⁇ 0.05 (i.e. the chance of a type I error is less than 5%) as determined by an art-accepted measure of statistical significance appropriate to the experimental design. [0185] All references cited herein are incorporated by reference in their entirety.
- phosphonic acids were thought to be a poor replacement for carboxylic acids based on differences in geometry, size, and charge. Phosphonic acids can also show reduced binding affinities against enzymes that utilize or bind the analogous carboxylic acid. Phosphonic acids can also display differences in cellular and in vivo potency, oral bioavailability, pharmacokinetics, metabolism, and safety. T3 and previously reported T3 mimetics contain a carboxylic acid thought to be important for binding and activation of T3 responsive genes. The carboxylic acid may also be important in the transport and distribution of these compounds through various transport proteins. Transport proteins can enhance transport of certain compounds, particularly negatively charged compounds, to the nucleus. .
- the present Inventors discovered that the compounds of the present invention are effective in activating thyroid hormone responsive genes and for the uses described herein, such as lowering cholesterol, even for compounds of the present invention that bind to the thyroid hormone receptors with reduced affinity as compared to the corresponding carboxylic acid derivative. Still further surprisingly, the present Inventors discovered that the compounds of the present invention have a high enough tissue selectivity and have a therapeutic index great enough to be efficacious in treating the diseases and disorders described herein while avoiding undesired side-effects involving the heart.
- the phosphonic acid- or phosphonic acid monoester- containing compounds, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs used in these methods cause at least a 50%, 2 fold, 3 fold, 4 fold, 6 fold or 8 fold increase or decrease in the expression of one or more thyroid hormone-responsive genes. Changes in gene expression can be detected in cells or in vivo. Prodrugs of the phosphonic acid- or phosphonic acid monoester-containing compounds can increase cellular uptake but in some cases are poorly converted to the phosphonic acid or monoester due to low levels of the enzymes required for the conversion.
- the liver is a major target organ of thyroid hormone with an estimated
- T3 mimetics in these methods would minimize effects on thyroid function, thyroid production of circulating iodinated thyronines such as T3 and T4, and/or the ratio of T3 to T4.
- the compounds or the present invention distribute more readily to the liver and result in pharmacological effects at doses that do not adversely affect thyroid function, thyroid production of circulating iodinated thyronines such as T3 and T4, and/or the ratio of T3 to T4.
- the phosphonic acid- or phosphonic acid monoester-containing thyromimetics and their prodrugs and salts are useful for significantly lowering cholesterol levels without having a significant effect on TSH levels, hi another embodiment, the compounds of the present invention significantly lower cholesterol levels without lowering TSH levels by more than 30%, 25%, 20%, 15%, 10%, or 5%.
- Mitochondria are the fuel source for all cellular respiration.
- the synthesis of new mitochondria is a complex process which requires over 1000 genes (Goffart et al, Exp. Physiol. 88(l):33-40 (2003)).
- the mechanisms which control mitochondrial biogenesis are not well defined, but are known to include exercise (Jones et al, Am. J. Physiol. Endocrinol. Metab. 284(1): ⁇ 96- 101 (2003)), overexpression of PGC-I (Lehman et al, J. CHn. Invest. 106(7):847-56 (2000)) or AMP activated protein kinase (Bergeron et al, Am. J. Physiol Endocrinol.
- phosphonic acid- or phosphonic acid monoester- containing thyromimetics and their prodrugs and salts may be used to cause weight loss or prevent weight gain without side effects. It may be advantageous to use compounds that result in high liver specificity (Examples F and G).
- compounds that result in increased levels of genes associated with oxygen consumption, e.g., GPDH (Example B) are particularly useful in weight loss and controlling weight gain.
- compounds that show weight loss at doses that do not affect cardiac function e.g., heart rate, force of systolic contraction, duration of diastolic relaxation, vascular tone, or heart weight, may be particularly useful in weight loss and controlling weight gain.
- compounds that cause weight loss without affecting thyroid function, thyroid production of circulating iodinated thyronines such as T3 and T4, and/or the ratio of T3 to T4 are particularly useful.
- Compounds of this invention while they mimic T3, result in preferential activation of liver T3 genes, are not expected to increase lipolysis in peripheral tissues which is expected to avoid the T3-induced higher circulating levels of free fatty acids and their effects on increasing gluconeogenesis flux and decreasing insulin sensitivity. Increased hepatic insulin sensitivity will decrease PEPCK and glucose 6-phosphatase gene expression thus reducing gluconeogenesis. TR activation in the liver should also decrease liver fat content, which in turn is expected to improve diabetes and steatohepatitis ⁇ e.g., NASH), thus providing another use for the compounds of the present invention.
- TH therapy results in increased energy expenditure. Increased energy expenditure can result in increased weight loss, which in turn can result in improved glycemic control. Diet and exercise are often used initially to treat diabetics. Exercise and weight loss increase insulin sensitivity and improve glycemia. Thus, further uses of the compounds of the present invention include increasing energy expenditure, increasing insulin sensitivity and improving glycemia.
- the compounds of the present invention have a therapeutic index, defined as the difference between the dose at which a significant effect is observed for a use disclosed herein, e.g., lowering cholesterol, and the dose at which a significant effect on a property or function, as disclosed herein (e.g., heart rate), is observed, is at least 50 fold, 100 fold, 200 fold, 300 fold, 400 fold, 500 fold, 600 fold, 700 fold, 800 fold, 900 fold, 1000 fold, 2000 fold, 3000 fold, 4000 fold, 5000 fold, 6000 fold, 7000 fold, 8000 fold, 9000 fold or at least 10000 fold.
- a therapeutic index defined as the difference between the dose at which a significant effect is observed for a use disclosed herein, e.g., lowering cholesterol, and the dose at which a significant effect on a property or function, as disclosed herein (e.g., heart rate), is observed, is at least 50 fold, 100 fold, 200 fold, 300 fold, 400 fold, 500 fold, 600 fold, 700 fold, 800 fold, 900
- Examples of said use disclosed herein includes but is not limited to reducing lipid levels, increasing the ratio of HDL to LDL or apoAI to LDL, reducing weight or preventing weight gain, maintaining or improving glycemic control, lowering blood glucose levels, increasing mitochondrial biogenesis, increasing expression of PGC-I, AMP activated protein kinase or nuclear respiratory factor, inhibiting hepatic gluconeogenesis or for the treatment or prevention of a disease or disorder selected from the group consisting of atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, fatty liver/steatosis, NASH, NAFLD, nephrotic syndrome, chronic renal failure, insulin resistance, diabetes, metabolic syndrome X, impaired glucose tolerance, hyperlipidemia, coronary heart disease, thyroid disease, thyroid cancer, depression, glaucoma, cardiac arrhythmias, heart failure, and osteoporosis.
- a disease or disorder selected from the group consisting of atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, fatty liver
- cardiac property/function examples include but are not limited to cardiac hypertrophy (heart weight to body weight ratio), heart rate, and various hemodynamic parameters, including systolic and diastolic arterial pressure, end systolic left ventricular pressure and maximal speeds of contraction and relaxation.
- genes such as spot-14, FAS, mGPDH, CPT-I, and LDL receptor are monitored. Changes of >1.5 fold in two or more genes is considered proof that the compound modulates T3 -responsive genes in vivo.
- Alternative methods for measuring changes in gene transcription include monitoring the activity or expression level of the protein encoded by the gene. For instance, in cases where the genes encode enzyme activities (e.g., FAS, mGPDH), direct measurements of enzyme activity in appropriately extracted liver tissue can be made using standard enzymological techniques. In cases where the genes encode receptor functions (e.g., the LDL receptor), ligand binding studies or antibody-based assays (e.g., Western blots) can be performed to quantify the number of receptors expressed.
- the effect on cholesterol is determined using cholesterol fed animals such as normal rats and hamsters, or TRa " " knockout mice. Cholesterol is measured using standard tests.
- Compounds of the present invention were tested using the methods described in Example D and I. Hepatic glycogen levels are determined from livers isolated from treated animals. Compounds of the present invention were tested using the methods described in Examples D and E. Changes in energy expenditure are monitored by measuring changes in oxygen consumption (MVo )• A variety of methods are well described in the literature and include measurement in the whole animal using Oxymax chambers (U.S. Patent No. 6,441,015). Livers from treated rats can also be evaluated (Fernandez et ah, Toxicol. Lett.
- Another aspect is compounds that in the presence of liver cells or microsomes result in compounds of Formula I, II, III, VIII, and X wherein X is phosphonic acid or phosphonic acid monoester.
- Also provided are methods of reducing plasma lipid levels in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof.
- said compound is an active form, m another embodiment said compound is a prodrug.
- said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter, is enantiomerically enriched or diastereomerically enriched, or a stereoisomer covered later.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture.
- said compound is a administered as a diastereomerically enriched mixture.
- said compound is administered as an individual stereoisomer.
- said compound is an active form.
- said compound is a prodrug.
- said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture.
- said compound is administered as a diastereomeric mixture.
- said compound is administered as an individual stereoisomer.
- said methods of reducing cholesterol results in a lowering of total cholesterol.
- said methods of reducing cholesterol results in a reduction of high density lipoprotein (HDL).
- said methods of reducing cholesterol results in a reduction of low density lipoprotein (LDL).
- said methods of reducing cholesterol results in a reduction of very low density lipoprotein (VLDL).
- said LDL is reduced to a greater extent than said HDL.
- said VLDL is reduced to a greater extent than said HDL.
- said VLDL is reduced to a greater extent than said LDL.
- the lipid is triglycerides, hi one embodiment said lipid is liver triglycerides, hi another embodiment said lipid is in the form of a lipoprotein, hi another embodiment said lipoprotein is Lp(a). hi another embodiment said lipoprotein is apoAII.
- HDL to VLDL, LDL to VLDL, apoAl to LDL or apoAI to VLDL in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof.
- said compound is an active form.
- said compound is a prodrug.
- said compound of Formula I, II, III, VIII and X, or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture.
- said compound is administered as a diastereomeric mixture.
- said compound is administered as an individual stereoisomer.
- said compound is an active form, hi another embodiment said compound is a prodrug, hi another embodiment said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture.
- said compound is a administered as a diastereomeric mixture, hi still another embodiment said compound is administered as an individual stereoisomer.
- said compound is administered as a racemic mixture, hi another embodiment said compound is administered as an enantiomerically enriched mixture, hi another embodiment said compound is a administered as a diastereomeric mixture, hi still another embodiment said compound is administered as an individual stereoisomer.
- Also provided are methods of reducing weight or preventing weight gain in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof.
- said compound is an active form.
- said compound is a prodrug.
- said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture.
- said compound is a administered as a diastereomeric mixture.
- said compound is administered as an individual stereoisomer.
- Also provided are methods of preventing or treating obesity in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof, hi one embodiment said compound is an active form.
- Li another embodiment said compound is a prodrug, hi another embodiment said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- hi another embodiment said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture, hi another embodiment said compound is a administered as a diastereomeric mixture, hi still another embodiment said compound is administered as an individual stereoisomer.
- Also provided are methods of preventing or treating coronary heart disease in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof, hi one embodiment said compound is an active form, hi another embodiment said compound is a prodrug, hi another embodiment said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- hi another embodiment said compound is administered as a racemic mixture
- hi another embodiment said compound is administered as an enantiomerically enriched mixture
- hi another embodiment said compound is a administered as a diastereomeric mixture.
- said compound is administered as an individual stereoisomer.
- Also provided are methods of maintaining or improving glycemic control in an animal being treated with a T3 mimetic comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof.
- said compound is an active form.
- said compound is a prodrug.
- Li another embodiment said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture, hi another embodiment said compound is administered as a diastereomeric mixture.
- Also provided are methods of lowering blood glucose levels in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof, hi one embodiment said compound is an active form, hi another embodiment said compound is a prodrug.
- said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture, hi another embodiment said compound is administered as an enantiomerically enriched mixture.
- said compound is a administered as a diastereomeric mixture, hi still another embodiment said compound is administered as an individual stereoisomer.
- Also provided are methods of preventing or treating thyroid disease, thyroid cancer, depression, glaucoma, cardiac arrhythmias, heart failure, or osteoporosis in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X or a pharmaceutically acceptable salt or co-crystal thereof.
- said compound is an active form.
- said compound is a prodrug, hi another embodiment said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture, hi another embodiment said compound is a administered as a diastereomeric mixture, hi still another embodiment said compound is administered as an individual stereoisomer.
- Also provided are methods of increasing mitochondrial biogenesis in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof, hi one embodiment said compound is an active form, hi another embodiment said compound is a prodrug, hi another embodiment said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- Also provided are methods of increasing expression of PGC-I, AMP activated protein kinase or nuclear respiratory factor in an animal comprising the step of administering to a patient an amount of a compound of Formula I, II, III, VIII, and X, a prodrug thereof, or a pharmaceutically acceptable salt or co-crystal thereof.
- said compound is an active form.
- said compound is a prodrug.
- said compound of Formula I, II, III, VIII, and X or a prodrug thereof comprises a stereocenter.
- said compound is administered as a racemic mixture.
- said compound is administered as an enantiomerically enriched mixture.
- said compound is a administered as a diastereomeric mixture.
- said compound is administered as an individual stereoisomer.
- the compounds of the present invention may be either crystalline, amorphous or a mixture thereof.
- Compositions comprising a crystalline form a compound of the present invention may contain only one crystalline form of said compound or more than one crystalline form.
- the composition may contain two or more different polymorphs. The polymorphs
- compositions herein having a base functional group are also included in the present invention.
- Pharmaceutically acceptable acid addition salts refer to those salts which retain the biological effectiveness and properties of the free base, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic acid or an organic acid to the free base.
- Salts derived from inorganic acids include, but are not limited to, acistrate, hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, besylate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate. bromide, fumarate, pamoate, glucouronate, hydroiodide, iodide, sulfate, xinofoate and chloride salts
- the compound of Formula X is a compound of Formula I wherein G is -O-, T is -(CH 2 ) 0 - 4 -, R 1 and R 2 are independently halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons, R 3 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons, R 4 is hydrogen, and R 5 is -OH, then X is not -P(O)(OH) 2 or -P(O)(O-lower alkyl) 2 .
- Ar 1 and Ar 2 are aryl groups
- G is an atom or group of atoms that links Ar 1 and Ar 2 through a single C, S, Se, O, or N atom or through two C atoms or through one C and one S atom or through one C and one O atom, wherein C and N are substituted;
- the compound has a Ki ⁇ 15OnM.
- Another embodiment includes a pharmaceutical composition comprising the compound and a at least one excipient.
- the pharmaceutical composition has a bioavailability of at least 15%.
- the compound is crystalline.
- the pharmaceutical composition is a unit dose.
- the invention relates to a compound of Formula I:
- R 54 is hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
- R 53 is selected from hydrogen, halogen, hydroxyl, mercapto, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, Ci-C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio; and
- Each R a is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 4 alkyl, halogen, -OH, optionally substituted -0-C 1 -C 4 alkyl, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -S-Ci-C 4 alkyl, -NR b R c , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom;
- Each R b is independently selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl;
- R 1 and R 2 are each independently selected from the group consisting of halogen, optionally substituted -Ci-C 4 alkyl, optionally substituted -S-Ci-C 3 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -0-C 1 -C 3 alkyl, and cyano;
- Each R d is selected from the group consisting of optionally substituted -C 1 -C 12 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -C 12 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, optionally substituted
- R f and R g are each independently selected from the group consisting of hydrogen, optionally substituted -C 1 -C 12 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -C 12 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, and optionally substituted -(CR b 2 ) n heterocycloalkyl, or R f and R s may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsarurations, which may contain a second heterogroup selected from the group of O, NR C , and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -Ci -C 4 alkyl, -OR b , oxo, cyan
- Y and Y' are each independently selected from the group consisting of-0-, and -NR V -; when Y and Y' are both -0-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R Z ) 2 OC(O)NR Z 2 , -NR z -C(0)-R y , -C(R z ) 2 -0C(0)R y , -C(R z ) 2 -0-C(0)0R y , -C(R z ) 2 0C(0)SR y , -alkyl-S-C(O)R y , -alkyl-S-S-alky
- Z is selected from the group consisting of -CHR 2 OH, -CHR 2 OC(O)R 5 ',
- Each R 2 is selected from the group consisting of R y and -H;
- Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- Each R x is independently selected from the group consisting of -H, and alkyl, or together R x and R x form a cycloalkyl group;
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl; with the provisos that: a) V, Z, W, W are not all -H; and b) when Z is -R z , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.
- the invention relates to a compound of Formula I:
- G, T, k, m, n, p, R a , R b , R c , R 1 , R 2 , R 3 , R 4 , R d , R e , R f , R g , R h , R 5 , X, V, W, W, Z, q, R z , R y , R x , and R v are as defined above;
- Y and Y' are each independently selected from the group consisting of-O-, and -NR V -; when Y and Y' are both -O-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R Z ) 2 OC(O)NR Z 2 , -NR z -C(O)-R y , -C(R z ) 2 -OC(O)R y , -C(R z ) 2 -O-C(O)OR y , -C(R z ) 2 OC(O)SR y , -alkyl-S-C(O)R y , -alky
- R 11 attached to -NR V - is independently selected from the group consisting of -H, -[C(R z ) 2 ] q -C00R y , -C(R ⁇ 2 COOR 3 ', -[C(R z ) 2 ] q -C(O)SR y , and -cycloalkylene-COOR y
- R 1 and R 2 are independently chosen from the group consisting of hydrogen, halogen, -C 1 -C 4 alkyl, R 3 is -C(O)NR 25 R 26 , -CH 2 -NR 25 R 26 , -NR 25 -C(O)R 26 , -OR 27 , R 28 , or R 29 ⁇ -o
- R 4 is hydrogen, halogen, cyano or alkyl
- R 5 is -OH
- R 25 and R 26 are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl
- R 27 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl
- R 28 is aryl, heteroaryl, or cycloalkyl
- R 29 is hydrogen, aryl, heteroaryl, alkyl, aralkyl, heteroaralkyl, then X is not -P(O)(OH) 2 , or -P(O)(O-lower alkyl) 2 ; b) when G is -0-, -S-, -Se-, -S(O)-, -S(O) 2 -, -CH 2 -, -CF 2 -, -C(O)-, -NH-
- A is selected from the group consisting of -NR 1 -, -O-, and -S-;
- R 1 is selected from the group consisting of hydrogen, -C(O)C 1 -C 4 alkyl, and -C 1 -C 4 alkyl;
- R b is selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl
- R 54 is hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
- R 53 is selected from hydrogen, halogen, hydroxyl, mercapto, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio; and
- R 52 is selected from hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 - C 4 alkynyl, C 1 -C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;
- D is selected from the group consisting of a bond, -(CR a 2 )-, and -C(O)-;
- Each R a is independently selected from the group consisting of hydrogen, optionally substituted -C 1 -C 4 alkyl, halogen, -OH, optionally substituted -0-C 1 -C 4 alkyl, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -S-C 1 -C 4 alkyl, -NR b R c , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom;
- R 1 and R 2 are each independently selected from the group consisting of halogen, optionally substituted -C 1 -C 4 alkyl, optionally substituted -S-C 1 -C 3 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -0-C 1 -C 3 alkyl, and cyano;
- R is selected from the group consisting of hydrogen, halogen, optionally substituted -C 1 -C 4 alkyl, optionally substituted -S-C 1 -C 3 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -0-C 1 -C 3 alkyl, hydroxy, -(CR a 2 )aryl, -(CR a 2 )cycloalkyl, -(CR a 2 )heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, -C(O)alkyl and cyano;
- Each R d is selected from the group consisting of optionally substituted -C 1 -C 12 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -Ci 2 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, optionally substituted
- Each R e is selected from the group consisting of optionally substituted -Ci-Ci 2 alkyl, optionally substituted -C 2 -Ci 2 alkenyl, optionally substituted -C 2 -C 12 alkynyl, optionally substituted -(CR a 2 ) n aryl, optionally substituted -(CR a 2 ) n cycloalkyl, and optionally substituted -(CR a 2 ) n heterocycloalkyl;
- R and R g are each independently selected from the group consisting of hydrogen, optionally substituted -Ci-Ci 2 alkyl, optionally substituted -C 2 -Ci 2 alkenyl, optionally substituted -C 2 -Ci 2 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, and optionally substituted -(CR b 2 ) n heterocycloalkyl, or R f and R s may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR C , and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -Ci-C 4 alkyl, -OR b , oxo, cyan
- Each R h is selected from the group consisting of optionally substituted -Ci-Ci 2 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -Ci 2 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, and optionally substituted -(CR b 2 ) n heterocycloalkyl; or
- R 3 and R 8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0- 2 unsaturations, not including the unsaturation on the ring to which R 3 and R 8 are attached, including 0 to 2 heteroatoms independently selected from -NR h -, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or
- R 3 and R 5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R 3 and R 5 are attached, including O to 2 heteroatoms independently selected from -NR h -, -0-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;
- X is P(O)YR 11 Y 5 R 11 ;
- Y and Y' are each independently selected from the group consisting of-0-, and -NR V -; when Y and Y' are both -0-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R Z ) 2 OC(O)NR Z 2 , -NR z -C(0)-R y , -C(R z ) 2 -0C(0)R y , -C(R z ) 2 -0-C(0)0R y , -C(R z ) 2 OC(O)SR y , -alkyl-S-C(O)R y , -alkyl-S-S-al
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 — 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or or together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen
- Each R z is selected from the group consisting of R y and -H;
- Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- Each R x is independently selected from the group consisting of -H, and alkyl, or together R x and R x form a cycloalkyl group;
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl; with the provisos that: a) V, Z, W, W are not all -H; and b) when Z is -R z , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.
- the invention relates to a compound of Formula II:
- A, B, R, R b , G, D, R a , R 1 , R 2 , R 8 , R 3 , R 4 , R d , ,R e , R f , R s , R h , R 5 , X, V, W, W, Z, q, R z , R y , R x , and R v are defined as above;
- Each R z is selected from the group consisting of R y and -H;
- Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl; with the provisos that: a) V, Z, W, W are not all -H; and b) when Z is -R z , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.
- the invention relates to a compound of Formula III:
- R 54 is hydrogen, halogen, Ci-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
- R 53 is selected from hydrogen, halogen, hydroxyl, mercapto, Ci-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio; and
- R 52 is selected from hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 - C 4 alkynyl, C 1 -C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;
- Each R c is independently selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl, optionally substituted -C(O)-C 1 -C 4 alkyl, and -C(O)H;
- R 1 and R 2 are each independently selected from the group consisting of halogen, optionally substituted -C 1 -C 4 alkyl, optionally substituted -S-C 1 -C 3 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -0-C 1 -C 3 alkyl, and cyano;
- R f and R g are each independently selected from the group consisting of hydrogen, optionally substituted -Ci-Ci 2 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -C 12 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, and optionally substituted -(CR b 2 ) n heterocycloalkyl, or R f and R g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, which may contain a second heterogroup selected from the group consisting of O, NR C , and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -C 1 -C 4 alkyl, -OR b , oxo,
- Each R h is selected from the group consisting of optionally substituted -C 1 -C 12 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -C 12 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, and optionally substituted -(CR b 2 ) n heterocycloalkyl; or
- R 3 and R 8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0- 2 unsaturations, not including the unsaturation on the ring to which R 3 and R 8 are attached, including 0 to 2 heteroatoms independently selected from -NR h -, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or
- R 3 and R 5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R 3 and R 5 are attached, including O to 2 heteroatoms independently selected from -NR h -, -0-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;
- R 7 is selected from the group consisting of hydrogen, halogen, amino, hydroxyl, -0-Ci-C 4 alkyl, -OCF 3 , -OCHF 2 , -OCH 2 F, -CF 3 , -CHF 2 , -CH 2 F, cyano, -SH and -S-Ci-C 4 alkyl;
- Y and Y' are each independently selected from the group consisting of-O-, and -NR V -; when Y and Y' are both -O-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl,
- R 11 attached to -NR V - is independently selected from the group consisting of -H, -[C(R z ) 2 ] q -C(O)OR y , -C(R x ) 2 C(O)OR y , -[C(R z ) 2 ] q -C(O)SR
- Each R x is independently selected from the group consisting of -H, and alkyl, or together R x and R x form a cycloalkyl group;
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl; with the provisos that: a) V, Z, W, W are not all -H; and b) when Z is -R z , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.
- the invention relates to a compound of Formula III:
- G, T, k, m, n, p, R a , R b , R c , R 1 , R 2 , R 8 , R 3 , R 4 , R d , R e , R f , R g , R h , R 5 , R 7 , X, V, W, W, Z, q, R z , R y , R x , and R v are defined as above;
- T is -A-B- where A is selected from the group consisting of -NR b -, -0-, -CH 2 - and -S- and B is selected from the group consisting of a bond and substituted or unsubstituted C 1 -C 3 alkyl;
- R 3 is selected from the group consisting of halogen, trifluoromethyl, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryloxy, substituted amide, sulfone, sulfonamide and C 3 -C 7 cycloalkyl
- R 54 is hydrogen, halogen, Ci-C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
- R 52 is selected from hydrogen, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 - C 4 alkynyl, C 1 -C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio;
- Each R a is independently selected from the group consisting of hydrogen, optionally substituted -C 1 -C 4 alkyl, halogen, -OH, optionally substituted -0-C 1 -C 4 alkyl, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -S-C 1 -C 4 alkyl, -NR b R c , optionally substituted -C 2 -C 4 alkenyl, and optionally substituted -C 2 -C 4 alkynyl; with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom;
- Each R b is independently selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl;
- Each R c is independently selected from the group consisting of hydrogen and optionally substituted -C 1 -C 4 alkyl, optionally substituted -C(O)-C 1 -C 4 alkyl, and -C(O)H;
- R 1 , R 2 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C 1 -C 4 alkyl, optionally substituted -S-C 1 -C 3 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted -0-C 1 -C 3 alkyl, and cyano; with the proviso that at least one of R 1 and R 2 is not hydrogen;
- R 8 and R 9 are each independently selected from the group consisting of hydrogen, halogen, optionally substituted -C 1 -C 4 alkyl, optionally substituted -S-C 1 -C 3 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, -CF 3 , -CHF 2 , -CH 2 F, -OCF 3 , -OCHF 2 , -OCH 2 F, optionally substituted-O-Ci-C 3 alkyl, hydroxy, -(CR a 2 )aryl, -(CR a 2 )cycloalkyl, -(CR a 2 )heterocycloalkyl, -C(O)aryl, -C(O)cycloalkyl, -C(O)heterocycloalkyl, - C(O)alkyl and cyano; or R 6 and T are taken together along with
- R 1 is selected from the group consisting of hydrogen, -C(O)C 1 -C 4 alkyl, -C 1 -C 4 alkyl, and -C 1 -C 4 -RTyI; or
- R 1 and R 7 are taken together along with the carbons to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R 1 and R 7 are attached, including O to 2 heteroatoms independently selected from -NR h -, -0-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; t is an integer from 3-6; - Ill -
- r and s are integers from 0-5;
- R f and R s are each independently selected from the group consisting of hydrogen, optionally substituted -C J -C I2 alkyl, optionally substituted -C 2 -C 12 alkenyl, optionally substituted -C 2 -Ci 2 alkynyl, optionally substituted -(CR b 2 ) n aryl, optionally substituted -(CR b 2 ) n cycloalkyl, and optionally substituted -(CR b 2 ) n heterocycloalkyl, or R f and R g may together form an optionally substituted heterocyclic ring of 3-8 atoms containing 0-4 unsaturations, said heterocyclic ring may contain a second heterogroup within the ring selected from the group consisting of O, NR C , and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-4 substituents selected from the group consisting of optionally substituted -C 1 -C 4 alkyl, -
- R 3 and R 8 are taken together along with the carbon atoms to which they are attached to form an optionally substituted ring of 5 to 6 atoms with 0- 2 unsaturations, not including the unsaturation on the ring to which R and R are attached, including 0 to 2 heteroatoms independently selected from -NR h -, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; or
- R 3 and R 5 are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations, not including the unsaturation on the ring to which R 3 and R 5 are attached, including O to 2 heteroatoms independently selected from -NR h -, -0-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom;
- Y and Y' are each independently selected from the group consisting of-0-, and -NR V -; when Y and Y' are both -0-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R Z ) 2 OC(O)NR Z 2 , -NR z -C(O)-R y , -C(R z ) 2 -OC(O)R y , -C(R z ) 2 -O-C(O)OR y , -C(R z ) 2 OC(O)SR y , -alkyl-S-C(O)R y , -alkyl-
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 — 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydrogen, hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon or carbon substituted by hydrogen,
- Each R z is selected from the group consisting of R y and -H;
- Each R x is independently selected from the group consisting of -H, and alkyl, or together R x and R x form a cycloalkyl group;
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl; with the provisos that: a) V, Z, W, W are not all -H; and b) when Z is -R z , then at least one of V, W, and W is not -H, alkyl, aralkyl, or heterocycloalkyl; and pharmaceutically acceptable salts and prodrugs thereof and pharmaceutically acceptable salts of said prodrugs.
- the invention relates to a compound of Formula VIII:
- G, T, k, m, n, p, R a , R b , R c , R 1 , R 2 , R 6 , R 7 , R ⁇ R 3 R 4 , R 5 , R 8 , R 9 , R d , R e , R f , R g , R h , X, V, W, W, Z, q, R z , R y , R x , and R v are defined as above;
- Y and Y' are each independently selected from the group consisting of-O-, and -NR V -; when Y and Y' are both -O-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl, -C(R Z ) 2 OC(O)NR Z 2 , -NR z -C(0)-R y , -C(R z ) 2 -OC(O)R y , -C(R z ) 2 -O-C(O)OR y , -C(R z ) 2 OC(O)SR y , -alkyl-S-C(O)R y , -alkyl-
- G, T, k, m, n, p, R a , R b , R°, R 1 , R 2 , R 6 , R 7 , R, R 3 , R 4 , R 5 , R 8 R 9 , R d , R e , R f , R g , R h , X, V, W, W, Z, q, R z , R y , R x , and R v are defined as above;
- Y and Y' are each independently selected from the group consisting of-O-, and -NR v s when Y and Y' are both -O-, R 11 attached to -O- is independently selected from the group consisting of -H, alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted CH 2 -heterocycloakyl wherein the cyclic moiety contains a carbonate or thiocarbonate, optionally substituted -alkylaryl,
- R 11 attached to -NR V - is independently selected from the group consisting of -H, -[C(R z ) 2 ] q -C(O)OR y , -C(R x ) 2 C(O)OR y , -[C(R z ) 2 ] q -C(O)SR y , and -cycloalkylene-COOR y ; when Y is -O- and Y' is NR V , then R 11 attached to -O- is independently selected from
- R 4 is hydrogen, halogen, cyano or alkyl
- R 5 is -OH
- R 25 and R 26 are each independently selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl
- R is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl
- R 28 is aryl, heteroaryl, or cycloalkyl
- R 29 is hydrogen, aryl, heteroaryl, alkyl, aralkyl, heteroaralkyl, then X is not -P(O)(OH) 2 , or -P(O)(O-lower alkyl) 2 ; b) when G is -O-, -S-, -Se-, -S(O
- R 50 and R 51 is oxygen and the other is -CH(R 54 )-, wherein R 54 is hydrogen, halogen, C 1 , C 2 , C 3 , or C 4 alkyl, C 2 , C 3 or C 4 alkenyl, C 2 , C 3 or C 4 alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl.
- R 50 and R 51 are sulphur and the other is -CH(R 54 )-, wherein R 54 is hydrogen, halogen, Ci, C 2 , C 3 , or C 4 alkyl, C 2 , C 3 or C 4 alkenyl, C 2 , C 3 or C 4 alkynyl, fluoromethyl, difluoromethyl, or trifluoromethyl.
- both R 50 and R 51 are -CH(R 53 )-, wherein R 53 is selected from hydrogen, halogen, hydroxyl, mercapto, Cj, C 2 , C 3 , or C 4 alkyl, C 2 , C 3 or C 4 alkenyl, C 2 , C 3 or C 4 alkynyl, Ci, C 2 , C 3 , or C 4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, fluoromethylthio, difluoromethylthio and trifluoromethylthio .
- T is -CH 2 -.
- T is selected from the group consisting of -(CR a 2 ) n -, -O(CR b 2 )(CR a 2 ) p -, -N(R c )(CR b 2 )(CR a 2 ) p -, -S(CR b 2 )(CR a 2 ) p -, -N(R b )C(O)-, and -CH 2 CH(NR c R b )-.
- T is -CH 2 CH(NH 2 )-.
- T is -N(H)C(O)-.
- T is -OCH 2 -.
- T is -O(CR b 2 )(CR a 2 ) n - or -NH(CR b 2 )(CR a 2 ) p -.
- T is -S(CR b 2 )(CR a 2 ) n -.
- T is -N(R c )(CR b 2 )(CR a 2 ) n -.
- T is -N(R b )C(O)(CR a 2 ) n -.
- T is -(CR a 2 ) n CH(NR b R c )-. In another aspect, T is -C(O)(CR a 2 ) m -. hi a further aspect, T is -(CR a 2 ) m C(O)-. hi another aspect, T is -(CR a 2 )C(O)(CR a 2 ) n -. In a further aspect, T is -(CR a 2 ) n C(O)(CR a 2 )-. In yet another aspect, T is -C(O)NH(CR b 2 )(CR a 2 ) p -.
- T is -O(CR b 2 )(CR a 2 ) n - or -NH(CR b 2 )(CR a 2 ) p -.
- T is -S(CR b 2 )(CR a 2 ) n -.
- T is -N(R°)(CR b 2 )(CR a 2 ) n -. In another aspect, T is -N(R b )C(O)(CR a 2 ) n -. In a further aspect, T is -(CR a 2 ) n CH(NR b R c )-. In another aspect, T is -C(O)(CR a 2 ) m -. hi a further aspect, T is -(CR a 2 ) m C(O)-. In another aspect, T is -(CR a 2 )C(O)(CR a 2 )n-.
- T is -(CR a 2 ) n C(O)(CR a 2 )-.
- T is -C(O)NH(CR b 2 )(CR a 2 ) p -.
- T is -(CR a 2 )i-2-O-(CR a 2 )i- 2 -.
- A is -NH-, -NMe-, -O-, and -S-.
- A is -NR 1 -.
- A is -O-.
- A is -S-.
- B is selected from
- B is -CH-, CMe-, and -N-.
- B is -CR b -.
- B is -N-.
- k is 0. hi a further aspect, k is 1. hi an additional aspect, k is 2. hi a further aspect, k is 3. hi yet another aspect, k is 4. hi one aspect m is 0. hi a further aspect, m is 1. In an additional aspect, m is 2. hi a further aspect, m is 3. hi one aspect n is 0. hi a further aspect, n is 1. hi an additional aspect, n is 2. In one aspect, p is 0. hi another aspect, p is 1.
- each R a is hydrogen with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom, hi another aspect, each R a is optionally substituted -C 1 -C 4 alkyl with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is halogen with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is -OH with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is optionally substituted -0-C 1 -C 4 alkyl with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is -OCF 3 , -OCHF 2 , or -OCH 2 F, with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is optionally substituted -S-C 1 -C 4 alkyl with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is -NR b R c with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is optionally substituted -C 2 -C 4 alkenyl with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- each R a is optionally substituted -C 2 -C 4 alkynyl with the proviso that when one R a is attached to C through an O, S, or N atom, then the other R a attached to the same C is a hydrogen, or attached via a carbon atom.
- R b is hydrogen. In an additional aspect, R b is optionally substituted -C 1 -C 4 alkyl.
- R c is hydrogen. In another aspect, R c is optionally substituted -C 1 -C 4 alkyl. In a further aspect, R c is optionally substituted -C(O)-C 1 -C 4 alkyl. In yet another aspect, R c is -C(O)H. [0294] For compounds of Formula I, in one aspect, R 1 and R 2 are each bromo.
- R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to
- R and R are independently halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons, hi a further aspect, R 1 and R 2 are the same and are selected from the group consisting of halogen, -C 1 -C 4 alkyl, -CF 3 , -CHF 2 , -CH 2 F, and cyano. In an additional aspect, R 1 and R 2 are different and are selected from the group consisting of halogen, -C 1 -C 4 alkyl, -CF 3 , -CHF 2 , -CH 2 F, and cyano.
- R 1 and R 2 are each independently selected from the group consisting of halogen, -C 1 -C 4 alkyl, -CF 3 , -CHF 2 , -CH 2 F, and cyano.
- R and R are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano.
- R 1 and R 2 are each iodo.
- R 1 and R 2 are both alkyl.
- R 1 and R 2 are each methyl, hi a further aspect, R 1 and R 2 are each chloro.
- R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, and methyl, hi an additional aspect, R 1 and R 2 are each halogen, hi another aspect, R 1 and R 2 are not both halogen. In another aspect, R 1 and R 2 are each optionally substituted -C 1 -C 4 alkyl. hi a further aspect, R 1 and R 2 are each optionally substituted -S-C 1 -C 3 alkyl. hi another aspect, R 1 and R 2 are each optionally substituted -C 2 -C 4 alkenyl. In a further aspect, R 1 and R 2 are each optionally substituted -C 2 -C 4 alkynyl.
- R 1 and R 2 are different and are selected from the group consisting of halogen, -C 1 -C 4 alkyl, -CF 3 , -CHF 2 , -CH 2 F, and cyano.
- R 1 and R 2 are each halogen, hi another aspect, R 1 and R 2 are not both halogen.
- R 1 and R 2 are each optionally substituted -C 1 -C 4 alkyl.
- R 1 and R 2 are each optionally substituted -S-C 1 -C 3 alkyl.
- R 1 and R 2 are each optionally substituted -C 2 -C 4 alkenyl.
- R 1 and R 2 are each optionally substituted -C 2 -C 4 alkynyl.
- R 1 and R 2 are each -CF 3 , -CHF 2 , or -CH 2 F.
- R 1 and R 2 are each -OCF 3 , -OCHF 2 , or -OCH 2 F.
- R 1 and R 2 are each optionally substituted-O-Q-Cs alkyl.
- R 1 and R 2 are each cyano.
- R and R are the same and are selected from the group consisting of halogen, -C 1 -C 4 alkyl, -CF 3 , -CHF 2 , -CH 2 F, and cyano.
- R 1 and R 2 are different and are selected from the group consisting of halogen, -C 1 -C 4 alkyl, -CF 3 , -CHF 2 , -CH 2 F, and cyano.
- R 1 and R 2 are each halogen.
- R 1 and R 2 are not both halogen.
- R , R , R , R , R , and R are each optionally substituted -C 1 -C 4 alkyl.
- R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each optionally substituted -S-C 1 -C 3 alkyl.
- R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each optionally substituted -C 2 -C 4 alkenyl.
- R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each optionally substituted -C 2 -C 4 alkynyl.
- R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each -CF 3 , -CHF 2 , or -CH 2 F. In a further aspect, R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each -OCF 3 , -OCHF 2 , or -OCH 2 F. In another aspect, R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each optionally substituted-O-Q-Qs alkyl. In a further aspect, R 1 , R 2 , R 6 , R 7 , R 8 , and R 9 are each cyano.
- R 6 and T are taken together along with the carbons they are attached to form an optionally substituted ring of 5 to 6 atoms with 0-2 unsaturations including 0 to 2 heteroatoms independently selected from -NR 1 -, -O-, and -S-, with the proviso that when there are 2 heteroatoms in the ring and both heteroatoms are different than nitrogen then both heteroatoms have to be separated by at least one carbon atom; and X is attached to this ring to either a carbon or a nitrogen by either -(CR a 2 )- or -C(O)- or a bond if X is attached directly to a carbon atom.
- R 6 and T are taken together along with the carbons they are attached to form a ring of 5 to 6 atoms containing 0 unsaturations. In another aspect, R 6 and T are taken together along with the carbons they are attached to form a ring of 5 to 6 atoms containing 1 unsaturation. R 6 and T are taken together along with the carbons they are attached to form a ring of 5 to 6 atoms containing 2 unsaturations.
- 0 to 2 heteroatoms are -NR 1 -.
- 0 to 2 heteroatoms are -O-.
- 0 to 2 heteroatoms are -S-.
- R 1 is hydrogen.
- R 1 is -C(O)C 1 -C 4 alkyl.
- R 1 is -C 1 -C 4 alkyl.
- R 1 is -Cj-C 4 -aryl.
- R 3 and R 4 are each hydrogen, hi another aspect, R 3 and R 4 are each halogen, hi a further aspect, R 3 and R 4 are each -CF 3 . In another aspect, R 3 and R 4 are each -OCF 3 . hi a further aspect, R 3 and R 4 are each cyano. In another aspect, R 3 and R 4 are each optionally substituted -C 1 -C 12 alkyl. hi a further aspect, R 3 and R 4 are each optionally substituted -C 2 -C 12 alkenyl. hi another aspect, R 3 and R 4 are each optionally substituted -C 2 -C 12 alkynyl.
- R 3 and R 4 are each optionally substituted -(CR a 2 ) m aryl.
- R 3 and R 4 are each optionally substituted -(CR a 2 ) m cycloalkyl.
- R 3 and R 4 are each optionally substituted -(CR a 2 ) m heterocycloaUcyl.
- R 4 is selected from the group consisting of hydrogen, halogen, -C 1 -C 4 alkyl, cyano and CF 3 .
- R 4 is hydrogen, hi a further aspect, R 3 is selected from the group consisting of halogen, optionally substituted -C 1 -C 6 alkyl, -CF 3 , cyano, -C(O)NR 1 R 8 , optionally substituted -(CR a 2 ) n aryl, -SO 2 NR f R g , and -SO 2 R 6 .
- R 3 is isopropyl or 4- fluorobenzyl.
- R d is optionally substituted -C 1 -C 12 alkyl. In a further aspect, each R d is optionally substituted -C 2 -C 12 alkenyl. hi another aspect, each R d is optionally substituted -C 2 -C 12 alkynyl. hi a further aspect, each R is optionally substituted -(CR b 2 ) n aryl. hi another aspect, each R is optionally substituted -(CR b 2 ) n cycloalkyl. hi a further aspect, each R is optionally substituted -(CR b 2 ) n heterocycloalkyl. In another aspect, each R d is -C(0)NR f R g . [0303] For compounds of Formula I, II, III, and VIII, in an additional aspect,
- R e is optionally substituted -C 1 -Ci 2 alkyl. In another aspect, R e is optionally substituted -C 2 -Ci 2 alkenyl. In a further aspect, R e is optionally substituted -C 2 -Ci 2 alkynyl. In another aspect, R e is optionally substituted -(CR a 2 ) n aryl. In a further aspect, R e is optionally substituted -(CR a 2 ) n cycloalkyl. In another aspect, R e is optionally substituted -(CR a 2 ) n heterocycloalkyl.
- R f and R g are each hydrogen, hi an additional aspect, R f and R g are each optionally substituted -Ci-Ci 2 alkyl. In another aspect, R f and R g are each optionally substituted -C 2 -Ci 2 alkenyl. hi an additional aspect, R f and R s are each optionally substituted -C 2 -Ci 2 alkynyl. hi a further aspect, R f and R s are each optionally substituted -(CR b 2 ) n aryl.
- R f and R g are each optionally substituted -(CR b 2 ) n cycloalkyl. In another aspect, R f and R g are each optionally substituted -(CR 2 ) n heterocycloalkyl.
- the optionally substituted heterocyclic ring may be substituted with 1 substituent selected from the group consisting of optionally substituted -Ci-C 4 alkyl, -OR b , oxo, cyano, -CF 3 , -CHF 2 , -CH 2 F, optionally substituted phenyl, and -C(O)OR h .
- the optionally substituted heterocyclic ring may be substituted with 2 substituents selected from the group consisting of optionally substituted -C 1 -C 4 alkyl, -OR b , oxo, cyano, -CF 3 , -CHF 2 , -CH 2 F, optionally substituted phenyl, and -C(O)OR h .
- the optionally substituted heterocyclic ring may be substituted with 3 substituents selected from the group consisting of optionally substituted -C 1 -C 4 alkyl, -OR b , oxo, cyano, -CF 3 , -CHF 2 , -CH 2 F, optionally substituted phenyl, and -C(O)OR 11 .
- the optionally substituted heterocyclic ring may be substituted with 4 substituents selected from the group consisting of optionally substituted -C 1 -C 4 alkyl, -0R b , oxo, cyano, -CF 3 , -CHF 2 , -CH 2 F, optionally substituted phenyl, and -C(O)OR 11 .
- R h is optionally substituted -Cj-C 12 alkyl.
- R h is optionally substituted -C 2 -Ci 2 alkenyl.
- R h is optionally substituted -C 2 -Ci 2 alkynyl.
- R h is optionally substituted -(CR b 2 ) n aryl.
- R h is optionally substituted -(CR b 2 ) n cycloalkyl.
- R h is optionally substituted -(CR b 2 ) n heterocycloalkyl.
- R 5 is selected from the group consisting of -OH, -OC(O)R 6 , -OC(O)OR 11 , -F, and -NHC(O)R 6 .
- R 5 is -OH.
- R 5 is optionally substituted -OCi-C 6 alkyl.
- R 5 is -OC(O)R 6 .
- R 5 is -OC(O)OR 11 .
- R 5 is -NHC(0)0R h .
- R 5 is -0C(0)NH(R h ).
- R 5 is -F.
- R 5 is -NHC(O)R 6 .
- R 5 is -NHC(O)NH(R 11 ).
- R 3 is iodo.
- R 3 is -CH(OH)(4-fluoro ⁇ henyl).
- X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCR z 2 OC(O)R y ] 2 , -P(O)[-OCR z 2 OC(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ][-OR ⁇ ], and -P(OX-OCH(V)CH 2 CH 2 O-], wherein V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCR z 2 OC(O)R y ] 2 , -P(O)[-OCR z 2 OC(O)OR y ] 2 , -P(O)[-Oalk-SC(O)R y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ][-OR ⁇ ] and -P(O)[-OCH(V)CH 2 CH 2 O-], wherein V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- X is selected from the group consisting of -P(O)[-OCR z 2 OC(O)R y ] 2 , -P(O)[-OCR z 2 OC(O)OR y ] 2 ,
- V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- X is selected from the group consisting of -PO 3 H 2 , -P(O)[ ⁇ OCH 2 OC(O)-t-butyl] 2 , -P(O)[-OCH 2 OC(O)O-/-propyl] 2 ,
- X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(O)-t-butyl] 2 , -P(O)[-OCH 2 OC(O)O-z ' -propyl] 2 , -P(O)[-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ] 2 , -P(O)C-N(H)C(CH 3 ) 2 C(O)OCH 2 CH 3 ] 2 ,
- X is -PO 3 H 2 .
- X is selected from the group consisting of -P(O)[-OCH 2 OC(OH-butyl] 2 and -P(O)[-OCH 2 OC(O)-?-propyl] 2 .
- X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(OH-butyl] 2 , -P(O)[-OCH 2 OC(O)O-i-propyl] 2 , -P(O)[-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ] 2 ,
- X is selected from the group consisting of -P(O)[-OCH 2 OC(O)O-ethyl] 2 and -P(O)[-OCH 2 OC(O)O-z ⁇ propyl] 2.
- X is selected from the group consisting of -P(O)[-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ] 2 and -P(O)[-N(H)C(CH 3 ) 2 C(O)OCH 2 CH 3 ] 2 .
- X is -P(OX-OCH 2 CH 2 SC(O)Me] 2 .
- X is selected from the group consisting of -P(OX-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ]
- this invention relates to Formulas I, II, III, or
- Y and Y' are each independently selected from the group consisting of -O-, and -NR V -.
- Y and Y' are each independently selected from the group consisting of -O-, and -NR V -; when Y and Y' are both -O- , R 11 attached to -O- is -H, alkyl.
- Y and Y' are each independently selected from the group consisting of -O-, and -NR V ⁇ ; when Y and Y' are both -O- , R 11 attached to -O- is optionally substituted aryl.
- Y and Y' are each independently selected from the group consisting of -O-, and -NR V -; when Y and Y' are both -O- , R 11 attached to -O- is optionally substituted heterocycloalkyl .
- Y and Y' are each independently selected from the group consisting of -0-, and -NR V -; when Y and Y' are both -O- , R 11 attached to -O- is optionally substituted CH 2 -heterocycloakyl.
- the cyclic moiety contains a carbonate or thiocarbonate.
- the cyclic moiety contains optionally substituted -alkylaryl.
- the cyclic moiety contains a -C(R Z ) 2 OC(O)NR Z 2 . In another aspect, the cyclic moiety contains -NR z -C(0)-R y . In another aspect, the cyclic moiety contains -C(R z ) 2 -OC(O)R y . In another aspect, the cyclic moiety contains -C(R z ) 2 -O-C(O)OR y . In a further aspect, the cyclic moiety contains -C(R z ) 2 OC(O)SR y . In another aspect, the cyclic moiety contains -alkyl-S-C(O)R y . In another aspect, the cyclic moiety contains -alkyl-S-S-alkylhydroxy. In a further aspect, the cyclic moiety contains -alkyl-S-S-alkylhydroxy.
- Y and Y' are both -NR V -.
- R 11 attached to -NR V - is -H.
- R 11 attached to -NR V - is -[C(R z ) 2 ] q -C(0)0R y .
- R 11 attached to -NR V - is -C(R x ) 2 C(O)OR y .
- R 11 attached to -NR V - is -[C(R z ) 2 ] q -C(O)SR y .
- R 11 attached to -NR V - is -cycloalkylene-C(O)OR y .
- Y is -O- and Y' is NR V .
- R 11 attached to -O- is -H.
- R 11 attached to -O- is alkyl.
- R 11 attached to -O- is optionally substituted aryl.
- R 11 attached to -O- is optionally substituted heterocycloalkyl.
- R 11 attached to -O- is optionally substituted CH 2 -heterocycloakyl.
- the cyclic moiety contains a carbonate or thiocarbonate.
- the cyclic moiety contains optionally substituted -alkylaryl.
- the cyclic moiety contains -C(R Z ) 2 OC(O)NR Z 2 .
- the cyclic moiety contains -NR z -C(0)-R y . In another aspect, the cyclic moiety contains -C(R Z ) 2 - OC(O)R y . In another aspect, the cyclic moiety contains -C(R z ) 2 -0-C(0)0R y . In a further aspect, the cyclic moiety contains -C(R z ) 2 OC(O)SR y . In another aspect, the cyclic moiety contains -alkyl-S-C(O)R y . m another aspect, the cyclic moiety contains -alkyl-S-S-alkylhydroxy. In a further aspect, the cyclic moiety contains -alkyl-S-S-alkylhydroxy.
- Y is -O- and Y' is NR V
- R 11 attached to -NR V - is -H.
- R 11 attached to -NR V - is -[C(R z ) 2 ] q -COOR y .
- R 11 attached to -NR V - is -CCR ⁇ COOR 7 .
- Y' are independently selected from -O- and -NR V -, then R 11 and R 11 together form a cyclic group comprising -alkyl-S-S-alkyl-.
- Y and Y' aarree iinnddeeppeendently selected from -O- and -NR V - and together R 1 ' and R 1 ' are the group:
- V is hydrogen.
- V is optionally substituted alkyl.
- V is optionally substituted aralkyl.
- V is heterocycloalkyl.
- V is aryl.
- V is substituted aryl.
- V is heteroaryl.
- V is substituted heteroaryl.
- V is optionally substituted 1-alkenyl.
- V is optionally substituted 1-alkynyl.
- W is hydrogen.
- W is optionally substituted alkyl.
- W is optionally substituted aralkyl.
- W is heterocycloalkyl.
- W is aryl.
- W is substituted aryl.
- W is heteroaryl.
- W is substituted heteroaryl.
- W is optionally substituted 1-alkenyl.
- W is optionally substituted 1-alkynyl.
- W is hydrogen.
- W is optionally substituted alkyl.
- W is optionally substituted aralkyl.
- W is heterocycloalkyl.
- W is aryl.
- W is substituted aryl.
- W is heteroaryl.
- W is substituted heteroaryl.
- W is optionally substituted 1-alkenyl.
- W is optionally substituted 1-alkynyl.
- V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon.
- the ring is substituted with hydroxyl attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus, hi another aspect, the ring is substituted with acyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus.
- the ring is substituted with alkylthiocarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus. In another aspect, the ring is substituted with alkoxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus. Li a further aspect, the ring is substituted with aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus.
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, that is fused to an aryl group at the beta and gamma position to the Y attached to the phosphorus.
- V and W are connected via an additional 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms and substituted with one substituent.
- the substituent is hydroxyl that is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus.
- the substituent is acyloxy that is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus.
- the substituent is alkoxycarbonyloxy that is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus.
- the substituent is alkylthiocarbonyloxy that is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus. In another aspect, the substituent is aryloxycarbonyloxy that is attached to one of said carbon atoms that is three atoms from a Y attached to the phosphorus.
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, wherein 0—1 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
- W and W are connected via an additional 2-5 atoms to form a cyclic group, wherein 0-2 atoms are heteroatoms and the remaining atoms are carbon, and V must be aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
- Z is -CH 2 NHaTyI.
- Z is -(CH 2 ) q -OR z .
- Z is -(CH 2 ) q -SR z .
- R 11 is not hydrogen, hi one aspect, q is 2. In a further aspect, q is 3.
- R y is alkyl. hi another aspect, R y is aryl. hi a further aspect, R y is heterocycloalkyl. hi another aspect, R y is aralkyl. [0332] For compounds of Formula I, II, III, and VIII, in one aspect, R x is -H.
- R x is alkyl. In yet another aspect, together R x and R x form a cycloalkyl group. [0333] For compounds of Formula I, II, III, and VIII, in one aspect, R v is -H.
- R v is lower alkyl.
- R v is acyloxyalkyl.
- R v is alkoxycarbonyloxyalkyl.
- R v is lower acyl.
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydroxy, acyloxy, alkylthiocarbonyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0-1 atoms are heteroatoms and the remaining atoms are carbon, that is fused to an aryl group
- Each R z is selected from the group consisting of R y and -H;
- Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl; and
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl.
- V is optionally substituted aryl.
- V is selected from the group consisting of 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 3 -fluorophenyl, pyrid-4-yl, ⁇ yrid-3-yl and 3,5-dichlorophenyl.
- the relative stereochemistry between the V-group substituent and T on the dioxaphosphonane ring is cis.
- the cis dioxaphosphonane ring has R stereochemistry at the carbon where V is attached.
- the cis dioxaphosphonane ring has S stereochemistry at the carbon where V is attached.
- R 11 is not hydrogen
- X is -P(O)YR 11 Y", wherein Y" is -C 1 -C 6 alkyl.
- Y is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
- X is PO 2 H 2 , P(O)(OH)(R z ),
- X is -P(O)(OH)(CH 3 ), -P(O)(OH)(CH 2 CH 3 ), -P(O)(OH)(isopropyl), or -P(O)(OH)(t-butyl).
- V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- R 4 is not hydrogen.
- G is selected from the group consisting of -O- and -CH 2 -; T is -OCH 2 -; R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R 4 is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is selected from the group consisting of -OH and -OC(O)R 0 ; R 3 is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted lower alkyl, optionally substituted -CH 2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclo
- G is -CH 2 -; T is -OCH 2 -; R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is iso-proTpyl; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCR z 2 OC(O)R y ] 2 , -P(O)[-OCR z 2 OC(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ][OR e ] and -P(O)[-OCR z (aryl)CH 2 CH 2 O-] .
- G is selected from the group consisting of -O- and -CH 2 -; T is -CH 2 -; R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is selected from the group consisting of -OH and -OC(O)R 6 ; R 3 is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted lower alkyl, optionally substituted -CH 2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohex
- R 4 is not hydrogen.
- R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is /-propyl; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[ ⁇ OCR z 2 OC(O)R y ] 2 , -P(O)[-OCR 2 2 OC(O)OR y ] 2 ,
- G is selected from the group consisting of -O- and -CH 2 -; T is -CH 2 CH 2 -; R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano; R is selected from the group consisting of hydrogen, iodo, 4-chlorophenyl, and cyclohexyl; R 5 is selected from the group consisting of -OH and -OC(O)R 6 ; R 3 is selected from the group consisting of hydrogen, iodo, bromo, optionally substituted lower alkyl, optionally substituted ' -CH 2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido wherein the amido group is selected from the group consisting of phenethylamino, piperidinyl, 4-methypiperizinyl, morpholinyl, cyclohe
- G is -O-; T is -CH 2 CH 2 -; R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is wo-propyl; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCR z 2 OC(O)R y ] 2 , -P(O)[-OCR z 2 OC(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ] 2 , -P(O)[-N(H)CR z 2 C(O)OR y ][OR e ] and -P(O)[-OCR z (aryl)CH 2 CH 2 O-] .
- G is -O-; T is -CH 2 CH 2 -; R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is iso- propyl; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(OHbutyl] 2 , -P(O)[-OCH 2 OC(O)O-z-propyl] 2 , -P(O)[-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ] 2 ,
- G is -O-
- T is -(CH 2 ) 0-4 -
- R 1 and R 2 are independently selected from the group consisting of hydrogen, halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons
- R 3 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons
- R 5 is -OH
- R 4 is not hydrogen
- G is -O-
- G is -CH 2 -; T is -OCH 2 -; R 1 and R 2 are each methyl; R 4 is hydrogen; R 5 is -OH; R 3 is iso-p ⁇ opyl; and X is -P(O)YR 11 Y 5 R 11 ; wherein Y and Y' are each independently selected from -O- and -NR V -; together R 11 and R 11 are the group:
- V, W, and W are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aralkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, optionally substituted 1-alkenyl, and optionally substituted 1-alkynyl; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group containing 5-7 atoms, wherein 0 - 1 atoms are heteroatoms and the remaining atoms are carbon, substituted with hydroxy, acyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from both Y groups attached to the phosphorus; or together V and Z are connected via an additional 3-5 atoms to form a cyclic group, wherein 0 - 1 atoms are heteroatoms and the remaining atoms are carbon, that is fused to an aryl group at the beta and gam
- Each R z is selected from the group consisting of R y and -H;
- Each R y is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- Each R v is selected from the group consisting of -H, lower alkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl, and lower acyl.
- V is aryl.
- Z is hydrogen, W is hydrogen, and W is hydrogen.
- V is 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 3 -fluorophenyl, pyrid-4-yl, pyrid-3-yl or 3,5-dichlorophenyl.
- the relative stereochemistry between the substituents on the dioxaphosphonane ring is cis.
- each R a is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 2 alkyl, halogen, -OH, optionally substituted -0-Ci-C 2 alkyl, -OCF 3 , optionally substituted -S-Ci-C 2 alkyl, -NR b R c , optionally substituted -C 2 alkenyl, and optionally substituted -C 2 alkynyl;
- Each R b is independently selected from the group consisting of hydrogen, optionally substituted -Ci-C 2 alkyl;
- Each R is selected from the group consisting of optionally substituted -Ci-C 6 alkyl, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, optionally substituted -(CR b 2 ) n phenyl, optionally substituted -(CR b 2 ) n monocyclic-heteroaryl, optionally substituted -(CR b 2 ) n -C 3 - C 6 -cycloalkyl, optionally substituted -(CR b 2 ) n -C 4 -C 5 -heterocycloalkyl, and -C(O)NR f R g ;
- Each R e is selected from the group consisting of optionally substituted -Ci-C 6 alkyl, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, optionally substituted -(CR b 2 ) n phenyl, optionally substituted -(CR ⁇ n monocyclic-heteroaryl, optionally substituted -(CR b 2 ) n -C 3 -C 6 -cycloalkyl, optionally substituted
- R f and R s are each independently selected from the group consisting of hydrogen, optionally substituted -C 1 -C 6 alkyl, optionally substituted -C 2 -C 6 alkenyl, optionally substituted -C 2 -C 6 alkynyl, optionally substituted -(CR b 2 ) n phenyl, optionally substituted -(CR b 2 ) n monocyclic- heteroaryl, optionally substituted -(CR b 2 ) n -C 3 -C 6 -cycloalkyl, optionally substituted -(CR b 2 ) n -C 4 -C 5 -heterocycloalkyl, or R f and R s may together form an optionally substituted heterocyclic ring, which may contain a second heterogroup selected from the group of O, NR b , and S, wherein said optionally substituted heterocyclic ring may be substituted with 0-2 substituents selected from the group consisting of
- Each R h is optionally substituted -Ci-Cj 6 alkyl, optionally substituted -C 2 -Ci 6 alkenyl, optionally substituted -C 2 -Ci 6 alkynyl, optionally substituted -(CR b 2 ) n phenyl, optionally substituted -(CR b 2 ) n monocyclic- heteroaryl, optionally substituted ⁇ (CR b 2 ) n -C 3 -C 6 -cycloalkyl, optionally substituted -(CR b 2 ) n -C 4 -C 5 -heterocycloalkyl.
- each R a is independently selected from the group consisting of hydrogen, methyl, fluoro, chloro, -OH, -0-CH 3 , -OCF 3 , -SCH 3 , -NHCH 3 , -N(CH 3 ) 2 ;
- Each R is independently selected from the group consisting of hydrogen, and methyl
- Each R c is independently selected from the group consisting of hydrogen, methyl, -C(O)CH 3 , -C(O)H;
- Each R is selected from the group consisting of optionally substituted -Ci-C 4 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, optionally substituted -(CH 2 ) n phenyl, optionally substituted -(CH 2 ) n monocyclic-heteroaryl, optionally substituted -(CH 2 ) n -C 3 -C 6 -cycloalkyl, optionally substituted
- Each R e is selected from the group consisting of optionally substituted -C 1 -C 4 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, optionally substituted -(CH 2 ) n phenyl, optionally substituted -(CH 2 ) n monocyclic-heteroaryl, optionally substituted -(CH 2 ) n -C 3 -C 6 -cycloalkyl, optionally substituted
- Each R is optionally substituted -C 1 -C 4 alkyl, optionally substituted -C 2 -C 4 alkenyl, optionally substituted -C 2 -C 4 alkynyl, optionally substituted -(CH 2 ) n phenyl, optionally substituted -(CH 2 ) n monocyclic- heteroaryl, optionally substituted -(CH 2 ) n -C 3 -C 6 -cycloalkyl, optionally substituted -(CH 2 ) n -C 4 -C 5 -heterocycloalkyl.
- G is selected from the group consisting of -O- and -CH 2 -; D is selected from the group consisting of a bond and -CH 2 -; A is selected from the group consisting of -NH-, -NMe-, -O-, and -S-; B is selected from the group consisting of -CH-, -CMe-, and -N-; R 1 and R 2 are each independently selected from the group consisting of halogen, -Cj-C 4 alkyl, -CF 3 , and cyano; R 4 is selected from the group consisting of hydrogen, halogen, -C 1 -C 4 alkyl, cyano and CF 3 ; R 5 is selected from the group consisting of -OH, -OC(O)R e , -OC(O)OR h , -F, and -NHC(O)R 6 ; R 3 is selected from the group consisting of halogen, optionally substitute
- V is selected from the group consisting of optionally substituted aryl, aryl, heteroaryl, and optionally substituted heteroaryl.
- G is selected from the group consisting of -O- and -CH 2 ;
- D is selected from the group consisting of a bond and -CH 2 -;
- A is selected from the group consisting of -NH-, -NMe-, -0-, and -S-;
- B is selected from the group consisting of -CH-, -CMe- and -N-;
- R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano;
- R 4 is selected from the group consisting of hydrogen and halogen;
- R 5 is selected from the group consisting of -OH and -OC(O)R 6 ;
- R 3 is selected from the group consisting of halogen, optionally substituted -Cj-C 6 alkyl, optionally substituted -CH 2 aryl, optionally substituted -CH(OH)aryl, -C(O)-amido, -S(
- G is -O-; D is a bond; A is -O-; B is selected from the group consisting of -CH- and -CMe-; R 1 and R 2 are each bromo; R is selected from the group consisting of hydrogen and iodo; R 5 is -OH; and R 3 is isopropyl.
- R 1 and R 2 are each chloro, R 3 is ⁇ opropyl, R 7 is fluoro and R 5 is -OH, then R 4 is not hydrogen.
- G is selected from the group consisting of oxygen, sulfur, sulfoxide, sulfonyl, -CH 2 -, -C(O)- and — NR b -;
- T is -A-B- where A is selected from the group consisting of -NR b -, -0-, -CH 2 - and -S- and B is selected from the group consisting of a bond and substituted or unsubstituted C 1 -C 3 alkyl;
- R 3 is selected from the group consisting of halogen, trifluoromethyl, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryloxy, substituted
- T is -N(H)C(O)-; G is -0-; R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is -wo-propyl; R 7 is fluoro; X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(OH-butyl] 2 ,
- T is -OCH 2 -; G is -0-; R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is wo-propyl; R 7 is fluoro; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(O)-t-butyl] 2 ,
- T is -CH 2 -;
- R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano;
- R is selected from the group consisting of hydrogen and iodo;
- R 5 is selected from the group consisting of -OH, and -OC(O)R e ;
- T is -CH 2 -; G is -O-; R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is z-propyl; R 7 is fluoro; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(O)-t-butyl] 2 ,
- T is -CH 2 CH 2 -;
- R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano;
- R 4 is selected from the group consisting of hydrogen and iodo;
- R 5 is selected from the group consisting of -OH and -OC(O)R 6 ;
- T is -CH 2 CH 2 -; G is -O-; R 1 and R 2 are each chloro; R 4 is hydrogen; R 5 is -OH; R 3 is zso-propyl; R 7 is fluoro; and X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(O)-t-butyl] 2 ,
- T is -NHCH 2 -;
- R 1 and R 2 are each independently selected from the group consisting of iodo, bromo, chloro, methyl, and cyano;
- R 4 is selected from the group consisting of hydrogen and iodo;
- R 5 is selected from the group consisting of -OH, and -OC(O)R e ;
- T is -NHCH 2 -; G is -O-; R 1 and R 2 are each chloro; R 4 is selected from the group consisting of hydrogen and iodo R 5 is -OH; R 3 is wo-propyl; and R 7 is fluoro.
- T is -NHCH 2 -; G is -O-; R 1 and R 2 are each bromo;
- R 1 and R 2 are each bromo;
- R 4 is selected from the group consisting of hydrogen and iodo
- R 5 is -OH;
- R 3 is wo-propyl;
- R 7 is fluoro;
- X is selected from the group consisting of -PO 3 H 2 , -P(O)[-OCH 2 OC(O)-t-butyl] 2 , -P(O)[-OCH 2 OC(O)O-z-propyl] 2 , -P(O)[-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ] 2 , -P(O)[-N(H)C(CH 3 ) 2 C(O)OCH 2 CH 3 ] 2 , -P(O)[-N(H)CH(CH 3 )C(O)OCH 2 CH 3 ] [3,4-methylenedioxyphenyl], -P(O)[-N(H)C(CH 3
- G is -O-; T is -CH 2 CH(NH 2 )-; R 1 and R 2 are each chloro; R 4 and R 8 are selected from the group consisting of hydrogen and iodo; R 5 is -OH; and R 3 is iodo.
- G is -O-; T is -N(H)C(O)-; R 1 and R 2 are each chloro; R 4 and R 8 are hydrogen; R 5 is -OH; and R 3 is -CH 2 (4-fluorophenyl).
- G is -O-; T is -OCH 2 -; R 1 and R 2 are each methyl; R 4 and R 8 are hydrogen; R 5 is -OH; and R 3 is ⁇ o-propyl.
- G is -O-; T is -CH 2 -; R 1 and R 2 are each chloro; R 4 and R 8 are hydrogen; R 5 is -OH; and R 3 is zjo-propyl.
- G is -O-; T is -CH 2 CH 2 -; R 1 and R 2 are each chloro; R and R 8 are hydrogen; R 5 is -OH; and R 3 is iso-propyl.
- G is -0-
- T is -(CH 2 ) O-4 -
- R 1 and R 2 are independently halogen, alkyl of 1 to 3 carbons, and cycloalkyl of 3 to 5 carbons
- R is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons
- R 4 is hydrogen
- R 5 is -OH
- X is not -P(O)(OH) 2 or -P(O)(O lower alkyl) 2 .
- R 5 is -NHC(O)R 6 , -NHS(-0) 1-2 R e , -NHC(S)NH(R h ), or -NHC(0)NH(R h )
- G is -0-; T is -CH 2 CH(NH 2 )-; R 1 and R 2 are each iodo; R 4 is selected from the group consisting of hydrogen and iodo; R 6 , R 7 , R 8 and R 9 are hydrogen; R 5 is -OH; and R 3 is iodo.
- G is -0-; T is -N(H)C(O)-; R 1 and R 2 are each methyl; R 4 , R 6 , R 7 , R 8 and R 9 are hydrogen; R 5 is -OH; and R 3 is -CH(OH)(4-fluorophenyl).
- G is -CH 2 -; T is -OCH 2 -; R 1 and R 2 are each methyl; R 4 , R 6 , R 7 , R 8 and R 9 are hydrogen; R 5 is -OH; and R 3 is isopropyl.
- G is -0-; T is -CH 2 -; R 1 and R 2 are each chloro; R 4 , R 6 , R 7 , R 8 and R 9 are hydrogen; R 5 is -OH; and R 3 is ir ⁇ -pr ⁇ pyl.
- the compound 1.3.6.7 from Formula V represents the compound of Formula V wherein V is 1, i.e., of group V is 1, i.e., of group -P(O)(OH) 2 ; V 2 is 3, i.e., of group -CH 2 -CH 2 -; V 3 is 6, i.e., of group methyl; and V 4 is 7, i.e., of group -SO 2 (4-fluorophenyl).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/137,773 US7514419B2 (en) | 2003-11-19 | 2005-05-26 | Phosphorus-containing thyromimetics |
US72517005P | 2005-10-06 | 2005-10-06 | |
PCT/US2006/020607 WO2006128055A2 (en) | 2005-05-26 | 2006-05-26 | Novel phosphorus-containing thyromimetics |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1891080A2 true EP1891080A2 (de) | 2008-02-27 |
Family
ID=37057345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06760469A Withdrawn EP1891080A2 (de) | 2005-05-26 | 2006-05-26 | Neue phosphorhaltige thyromimetika |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1891080A2 (de) |
JP (1) | JP2008545710A (de) |
CN (1) | CN101189248A (de) |
AU (1) | AU2006249347A1 (de) |
CA (1) | CA2606497A1 (de) |
MX (1) | MX2007014493A (de) |
WO (1) | WO2006128055A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
KR20190104524A (ko) * | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
WO2018226604A1 (en) * | 2017-06-05 | 2018-12-13 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
EP3768690A4 (de) * | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung |
WO2020118564A1 (en) * | 2018-12-12 | 2020-06-18 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
AU2019397067A1 (en) | 2018-12-12 | 2021-07-22 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
CN113784950A (zh) | 2019-03-01 | 2021-12-10 | 速通医疗公司 | 新型拟甲状腺素药 |
CN112300211B (zh) * | 2019-07-26 | 2023-12-08 | 广东东阳光药业股份有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
EP4019524A4 (de) * | 2019-08-19 | 2024-01-03 | Hepagene Therapeutics Hk Ltd | Heterocyclische thr-beta-rezeptor-agonistverbindung und verfahren zu ihrer herstellung und ihre verwendung |
CN110726801A (zh) * | 2019-10-31 | 2020-01-24 | 山东泰星新材料股份有限公司 | 一种监测烷基次膦酸反应状态的方法 |
CN113336792A (zh) * | 2020-02-18 | 2021-09-03 | 甘莱制药有限公司 | 一种环状膦酸酯化合物的制备方法 |
US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
CN114315902A (zh) * | 2020-09-30 | 2022-04-12 | 甘莱制药有限公司 | 一种甲状腺激素β受体激动剂的晶体及其制备方法和用途 |
CN114763363A (zh) * | 2021-01-12 | 2022-07-19 | 上海喀露蓝科技有限公司 | 磷酸或磷酸酯类衍生物及其制备方法和其在医药上的用途 |
WO2023158607A1 (en) * | 2022-02-18 | 2023-08-24 | Viking Therapeutics, Inc. | Polymorphic forms and methods of producing polymorphic forms of a compound |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3357887A (en) * | 1962-12-03 | 1967-12-12 | Upjohn Co | 4-phenoxy-3, 5-dihalophenylalkanols and hypocholesteremic compositions containing the same |
GB9713739D0 (en) * | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
IL137672A0 (en) * | 2000-08-03 | 2001-10-31 | Dpharm Ltd | Derivatives of branched-chain lipophilic molecules and uses thereof |
EP1469863A2 (de) * | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selektive s1p1/edg1-rezeptoragonisten |
US7829552B2 (en) * | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
-
2006
- 2006-05-26 WO PCT/US2006/020607 patent/WO2006128055A2/en active Application Filing
- 2006-05-26 MX MX2007014493A patent/MX2007014493A/es not_active Application Discontinuation
- 2006-05-26 CN CNA2006800177325A patent/CN101189248A/zh active Pending
- 2006-05-26 EP EP06760469A patent/EP1891080A2/de not_active Withdrawn
- 2006-05-26 JP JP2008513783A patent/JP2008545710A/ja not_active Withdrawn
- 2006-05-26 CA CA002606497A patent/CA2606497A1/en not_active Abandoned
- 2006-05-26 AU AU2006249347A patent/AU2006249347A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2006128055A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006128055A2 (en) | 2006-11-30 |
WO2006128055A3 (en) | 2007-05-24 |
AU2006249347A1 (en) | 2006-11-30 |
CN101189248A (zh) | 2008-05-28 |
JP2008545710A (ja) | 2008-12-18 |
MX2007014493A (es) | 2008-02-07 |
CA2606497A1 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1689383B1 (de) | Neue phosphor enthaltende thyromimetika | |
AU2006249348B2 (en) | Novel phosphinic acid-containing thyromimetics | |
EP1891080A2 (de) | Neue phosphorhaltige thyromimetika | |
US10925885B2 (en) | Thyromimetics for the treatment of fatty liver diseases | |
WO2011038207A1 (en) | Phosphorus-containing thyroid hormone receptor agonists and methods of use | |
CN101180097A (zh) | 新型含次膦酸的拟甲状腺素药 | |
SK12722002A3 (sk) | Inhibítory fruktóza-1,6-bisfosfatázy obsahujúce arylovú skupinu a ich použitie | |
IL86463A (en) | Phosphorus-containing compounds that prevent AOC reductase and pharmaceutical preparations that contain them | |
CA2764126A1 (en) | Diphenyl sulfide derivatives and medicines containing same as active ingredient | |
MXPA06004880A (en) | Novel phosphorus-containing thyromimetics | |
JP4880473B2 (ja) | ホスホン酸誘導体及び血中の高リン酸が関与する疾患の治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071227 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
17Q | First examination report despatched |
Effective date: 20080909 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090320 |